Published on
Jun 4, 2025
Earlier treatment with Pluvicto may be beneficial for patients with hormone-sensitive prostate cancer
New late-stage clinical trial findings signal that treatment with Pluvicto—a targeted radiotherapy for prostate cancer—may benefit more patients than previously believed. Swiss drugmaker Novartis shared the topline outcomes from Phase 3 of the PSMAddition …
Source:
Health Imaging
-
Neutral
